BioWorld

Oct. 11, 2002

View Archived Issues

House Members Grill FDA, ImClone On Approval Process

WASHINGTON - The series of missteps surrounding the application process for ImClone Systems Inc.'s cancer drug, Erbitux, has forced the FDA to rethink some of its procedures. (BioWorld Today) Read More

Genentech Meets Expectations, But Analysts Express Caution

Read More

Human Genome Reveals Malaria Resistance Gene Variations Over Past 10,000 Years Of Civilization

Read More

Northwest Biotherapeutics Cuts Back, Suspends Phase III Trial

Read More

Other News To Note

Read More